Gyeonggi-do,, Korea
Accelerating Drug Development using Oligonucleotides Since its discovery, RNA interference (RNAi) technology has been widely recognized as a novel drug development platform that could change the paradigm of therapeutic development. OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for OliX Pharmaceuticals on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
